gms | German Medical Science

86th Annual Meeting of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery

German Society of Oto-Rhino-Laryngology, Head and Neck Surgery

13.05. - 16.05.2015, Berlin

Article

Send article

The use of Omalizumab in the treatment of nasal polyps

Meeting Abstract

Search Medline for

  • corresponding author Anna Yakinthou - Praxis, Thessaloniki, Griechenland
  • Drosos Tsavlis - Praxis, Thessaloniki, Griechenland
  • Ioannis Megas - Praxis, Thessaloniki, Griechenland

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. 86. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. Berlin, 13.-16.05.2015. Düsseldorf: German Medical Science GMS Publishing House; 2015. Doc15hnod082

doi: 10.3205/15hnod082, urn:nbn:de:0183-15hnod0827

Published: March 26, 2015

© 2015 Yakinthou et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License. You are free: to Share - to copy, distribute and transmit the work, provided the original author and source are credited. See license information at http://creativecommons.org/licenses/by-nc-nd/3.0/.

Outline

Text

It is often that patients with nasal polyps may suffer from asthma. Both, nasal polyps and asthma, share the same features, inflammation, eosinophilia and local IgE formation. Omalizumab, as an anti-IgE mAb, is proven to be effective in treating allergic asthma. Could be, also, a treatment in nasal polyps.

Our target is to investigate the clinical efficacy of omalizumab in nasal polyps.

We have 7 patients with massive polyposis and asthma. Omalizumab was given at 2-or 4-week intervals, based on patient's body weight and IgE levels. After 16 weeks, we had an endoscopical reduction in nasal polyps, an improvement in spirometry, a reduction of nasal corticosteroids use and an improvement in the quality of life.

Omalizumab is effective in the symptoms of nasal congestion, anterior rhinorrhea, loss of smell, wheezing and dyspnea. This could be due to the local IgE formation in nose and lungs.

Der Erstautor gibt keinen Interessenkonflikt an.